Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed

GILEAD SCIENCES, INC.

2024-Q1 EPS reported -$3.34 revenue$6,686,000,000

GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.
Revenue up 5% to $6.7B; base business ex-Veklury up 6% to $6.1B.
Biktarvy up 10% to $2.9B; Oncology up 18% to $789M.
Full-year GAAP EPS guidance cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP to $3.45–$3.85 from $6.85–$7.25.
Cash $4.7B; operating cash flow $2.2B; dividends paid $990M; $400M stock buyback.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GILEAD SCIENCES, INC. reported the quarter ended March 31, 2024 results: revenue $6.7 billion, EPS $(3.34).

Period: the quarter ended March 31, 2024
Revenue: $6.7 billion
EPS: $(3.34)
Result: reported results

Exact text from the filing

providing updates on this and our broad Oncology portfolio throughout the rest of 2024.” First Quarter 2024 Financial Results • Total first quarter 2024 revenue increased 5% to $6.7 billion, compared to the same period in 2023, primarily due to higher HIV, Oncology and Liver Disease sales. • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000882095-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.